Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Territories
Dec 13, 2024•over 1 year ago
Contract Type
agreement
BiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
Newron Pharmaceuticals S.p.A. and EA Pharma Co., Ltd. have entered into a license agreement to develop, manufacture, and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories. The agreement includes an upfront payment of €44 million and financial contributions to Newron’s upcoming Phase III study, with total potential payments of up to €117 million
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months